ClinicalTrials.gg
Active, not recruitingNCT06396026Updated Jun 3, 2026

A Study of Efficacy and Safety of TLL-018 in CSU Participants

A Phase 3 interventional study of TLL-018 tablets and Placebo tablets in Chronic Spontaneous Urticaria, sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.

Enrollment
3rd of 30
440 · median 110
Started
2024
with 6 others
Phase 3
8 of 34
1 open now
Primary completion
2025-10
later than 1 of 19 live
Registered
15th of 34
by date
Lead sponsor
3 of 34
Hangzhou Highlightll Pharmaceutical Co., Ltd

Among the 34 studies in Chronic Urticaria with a site in China, this one is the 3rd largest by enrollment of the 30 interventional ones that give a count, is one of 7 that started in 2024, is one of 8 in phase 3, reaches primary completion later than 1 of the 19 other live ones, and was the 15th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Chronic Urticaria with a site in China, or all of them as a file.
02

Study summary

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) With Inadequate Controll to Second Generation H1-antihistamines.

Read the detailed description

This is a randomized, double-blind, single-dummy, placebo-parallel-group, phase 3 study to assess the safety and efficacy of TLL-018 in Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) participants who had an Inadequate Controll to Second Generation H1-antihistamines.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 75.
  • Diagnosis of CSU to secomd-generation H1-AH.
  • CSU diagnosis for ≥ 6 months.
  • The presence of itch and hivese despite current use of an approved dose of H1-AH prior to screening visit.
  • UAS7 score (range 0-42) ≥ 16 and itch component of UAS7 (range 0-21) ≥ 8 during 7 days prior to randomization (Day 1).
  • Participants were required to take a stable standard dose of a second generation H1-AH concomitantly according to local guidelines.
  • Willing and able to complete UPDD for the duration of the study.
  • Evidence of urticaria confirmed by the investigator prior to randomization.
  • Women of Child Bearing Potential () should not be pregnant or breastfeeding and the pregnancy test should be negative before randomization.
  • Participants (whether male or female) should have adequate barrier during the whole treatment period and at least 90 days after treatment; subjects should avoid the sperm or ovum donation for at least six months after treatment.

Exclusion criteria

Exclusion Criteria:

  • Participants meeting Chinese Guidelines for Urticaria Diagnosis and Treatment with the following concomitant diseases cannot be enrolled:

    1. Clearly defined underlying etiology for chronic urticarias other than CSU. E.g. induced urticaria, including but not limited to artificial urticaria.
    2. Any disease, which may have symptoms of urticaria and/or angioedema, including but not limited to urticaria and vasculitis.
    3. Suffering from other chronic pruritic diseases that may affect the judgment of efficacy results, such as psoriasis, atopic dermatitis, etc.
    4. Previous , herpes zoster, active tuberculosis.
    5. Other symptoms of progressive or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiovascular, neurological, psychiatric, or cerebral disease.
    6. Taking part in this study, in the opinion of the investigator, places the patient at unacceptable risk.
  • Participants with any of the following prior therapies or concomitant medications cannot be enrolled:

    1. Have received any study drug within 4 weeks or less than 5 elimination of half-life period before randomization (whichever is longer).
    2. Have received biological agent within 3 months or 5 elimination of half-life period prior to randomization (whichever is longer).
    3. Have received /modulatory drug within 4 weeks before randomization.
    4. Have received any within 2 months before randomization or plan to receive a live vaccine during the study.
  • Have experienced major surgery within 4 weeks before randomization, or expected to receive major surgical treatment after enrollment;
  • Have donated blood more than 400 ml or received blood transfusion within 3 months prior to the study.
  • History of drug or alcohol abuse within 6 months prior to screening.
  • Allergy to ingredients or of H1-AH or TLL-018.
  • Laboratory test results are abnormal and may interfere the study judged by investigators.
  • Participants are not appropriate for participation in any other situation or condition in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    Arm 1

    TLL018 tablets,1 tablet ,BID

    Drug: TLL-018 tablets

  • Placebo comparator
    Arm 2

    Placebo tablets, 1 tablet ,BID

    Drug: Placebo tablets

Interventions

  • Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks

  • DrugPlacebo tablets

    Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.

06

What researchers measure

Primary outcomes

  1. Change from baseline in UAS7 at Week 12

    To demonstrate that TLL-018 is superior to placebo in CSU with respect to change from baseline in UAS7 at Week 12 by assessing absolute change from baseline in weekly Urticaria Activity Score (UAS7) at week 12. The UAS7 is a scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.

    Time frame: 12 weeks

  2. Change from baseline in ISS7 at Week 12

    To demonstrate that TLL-018 is superior to placebo in CSU with respect to change from baseline in ISS7 at Week 12 by assessing absolute change from baseline in weekly Itch Severity Score (ISS7) at week 12. The ISS7 is the itch severity score for 7 days, and it ranges from 0 to 21.

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline in HSS7 at Week 12

    To demonstrate that TLL-018 is superior to placebo in CSU with respect to change from baseline in HSS7 at Week 12 by assessing absolute change from baseline in hive severity score (HSS7) at week 12. The HSS7 is the hive severity score for 7 days, and it ranges from 0 to 21.

    Time frame: 12 weeks

  2. Proportion of Participants With UAS7≤6 Response at Week 12

    To demonstrate that a greater proportion of participants achieve disease activity control UAS7≤6 at Week 12 who are treated with TLL-018 compared to placebo-treated participants by assessing achievement of UAS7≤6 at week 12.

    Time frame: 12 weeks

  3. Proportion of Participants With UAS7=0 Response at Week 12

    To demonstrate that a greater proportion of participants achieve complete absence of hives and itch (UAS7 = 0) at Week 12 who are treated with TLL-018 compared to placebo-treated participants by achievement of UAS7 = 0 at week 12.

    Time frame: 12 weeks

  4. Proportion of Participants With DLQI=0/1 Response at Week 12

    To demonstrate that a greater proportion of participants who are treated with TLL-018 achieve DLQI = 0/1 at Week 12 compared to placebo-treated participants by assessing achievement of DLQI = 0/1 at week 12.

    Time frame: 12 weeks

  5. Change from baseline in DLQI at Week 12

    To demonstrate that TLL-018 is superior to placebo in CSU with respect to change from baseline in DLQI at Week 12 by assessing absolute change from baseline in DLQI at week 12.

    Time frame: 12 weeks

  6. Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events

    To demonstrate the safety and tolerability of TLL-018 by assessing occurrence of treatment emergent adverse events and serious adverse events during the study.

    Time frame: 52 weeks

07

Study locations

1 site
  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences
    Nanjing, Jiangsu, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Oct 2025, 18 months.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 18 months is below that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 2, 2024
StartActual
Mar 27, 2024
Primary completionActual
Oct 23, 2025
CompletionEst.
Dec 30, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06396026
Responsible party
Sponsor
First posted
May 2, 2024
Start date
Mar 27, 2024
Primary completion
Oct 23, 2025
Completion
Dec 30, 2026 (estimated)
Last update
Jun 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TLL-018

Start the discussion